Would you ever consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC?

Answer from: Medical Oncologist at Academic Institution

This is a really interesting question as primary prospective trials in this setting are limited. Following progression of atezolizumab/bevacizumab, there was a recent abstract of a phase 2 trial using the combination regorafenib + pembrolizumab (N=95 patients, cohort 1 of 68 patients having received...

Comments

Medical Oncologist at Houston Cancer Treatment and Immunotherapy Center
Agree!

Answer from: Medical Oncologist at Community Practice

I would consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC.

Comments

Medical Oncologist at Mary Bird Perkins
Dr. @Nguyen, what about using atezolizumab-bevaciz...

Medical Oncologist at Mayo Clinic, Rochester
After durvalumab-tremelimumab, I would consider a ...

Please select the option that best describes you:

Would you ever consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC?

Related Questions